Product News and Recalls

FDA OKs Bayer contraceptive for heavy bleeding

The U.S. Food and Drug Administration has approved the use of German corporation Bayer’s birth control pill Natazia for the treatment of heavy menstrual bleeding, according to RTTNews.

The report quotes Bayer’s Dr. Flemming Ornskov as saying: “As the first combined oral contraceptive treatment for heavy menstrual bleeding, Natazia represents a non-invasive treatment approach for this medical condition in addition to our intrauterine system Mirena. Both products underline Bayer’s ongoing commitment to advancing women’s health by providing them with multiple treatment ...

continue reading...

March 2012 Yaz/Beyaz Settlement Update

The Court of Common Pleas in Philadelphia has delayed trial deadlines in the cases over Yaz/Yasmin/Beyaz birth control for another 60 days. This puts the deadlines in Philadelphia on par with the U.S. District Court, which issued an order extending deadlines on Feb. 29.

Judge Sandra Moss announced the latest extension on March 9, 2012, referencing the District Court order, which will allow the parties in the case more time to negotiate.

Lopez McHugh is representing multiple plaintiffs against Bayer Healthcare, ...

continue reading...

Report accuses maker of recalled artificial hips, J&J, of hypocrisy

A report by the American Association for Justice accuses the corporation Johnson & Johnson of hypocrisy for lobbying to prevent individual lawsuits against the company, while suing others to further its goals.

J&J is a board member of the Institute for Legal Reform, an arm of the U.S. Chamber of Commerce. The ILR has the stated goal of “tort reform,” which the AAJ translates as an attempt to restrict “access [to] the civil justice system” by individuals.

But even as the corporation ...

continue reading...

Bayer expects new drugs to generate billions

German corporation Bayer has announced that its four most promising drugs, led by newly-launched anti-clotting pill Xarelto, may account for combined annual sales of as much as $6.5 billion, according to a Reuters report.

The report says Bayer’s healthcare division is aiming for sales of roughly $26.2 billion in 2014, up from $22.4 billion last year.

The company said prescription drug sales were set to rise to about $15 billion by 2014, up 16 percent from 2011, fueled largely by new product ...

continue reading...

Consumer group calls for reform of FDA approval process

The independent nonprofit Consumer Reports has undertaken a national campaign to change the process by which the federal Food and Drug Administration approves medical devices, according to a report in the Chicago Tribune.

Consumer Reports says the agency’s approval of metal-on-metal hip implants and transvaginal mesh implants – both of which have led to thousands of reported cases of debilitating health problems — illustrate why reforming the process is necessary.

According to the Tribune, Consumer Reports President Jim Guest sent an email ...

continue reading...

Study: Temporary increased cancer risk from hormonal birth control

Medpage Today reports about a South African study that found a temporary increased risk of breast and cervical cancer associated with hormone contraceptives.

According to the study, women who recently used an injectable or oral hormone contraceptive were about 1.7 times more likely to develop breast cancer and 1.4 times more likely to develop cervical cancer than women who never used them, but the risk disappeared a few years after the women stopped taking the medication.

Numerous studies have also linked certain ...

continue reading...
Page 311 of 330 «...280290300309310311312313...»